Compare Gilead Sciences, Inc. (GILD) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Prudential Financial Inc — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Prudential Financial Inc trades at $117.49 (market cap $39.96B). The key difference: Gilead Sciences, Inc. is far larger — about 4.1× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.87%). Which is the better fit depends on your goals.
| GILD | PRU | |
|---|---|---|
Market Cap | $163.51B | $39.96B |
Sector | Health | Financials |
52-Week High | $155.80 | $118.72 |
52-Week Low | $108.22 | $92.00 |
Enterprise Value | $178.05B | $67.01B |
Dividend Yield | 2.49% | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Prudential Financial (PRU) trades at $114.79, down 1.19% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 11.85 and net income margin of 5.5%, supported by recent earnings beats. Recent news highlights retirement growth and international expansion, while a $1.40 dividend reinforces shareholder returns.
The outlook remains positive given earnings momentum and discounted valuation, though mixed analyst ratings and volatile cash flows pose risks. Upside potential hinges on continued execution in retirement services, while macroeconomic sensitivity and debt levels warrant monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
